echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Science Sub-Journal: Revealing that radiotherapy and immunotherapy restrict tumor progression by removing extramedullary red blood cell precursor cells

    Science Sub-Journal: Revealing that radiotherapy and immunotherapy restrict tumor progression by removing extramedullary red blood cell precursor cells

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    February 28, 2021 News/bioon.
    com" target="_blank">/---Targeted radiation is often used to research and treat different types of cancer.
    In a new study, researchers from China's Xi'an Jiaotong University, Shandong First Medical University, Shandong Qianfoshan Hospital, Xuzhou Medical University, the University of Chicago, and the University of Texas Southwestern Medical Center focused on one type of cell , They release a protein that enhances resistance to cancer therapy and promotes bioon.
    com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
    html">tumor progression.
    The relevant research results were published in the journal Science Translational Medicine on February 24, 2021, with the title of the paper "Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity".

    bioon.
    com" target="_blank">bioon.
    com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
    html">Tumor


    The picture comes from CC0 Public Domain.


    This research focused on Ter cells, which are extra medullary erythroid precurser cells that secrete the neuropeptide artemin.
    These researchers found that local tumor radiation therapy, immunotherapy or systemic combination of the two treatments can be consumed Ter spleen cells, reduce the production of artemin, and tumors outside the radiation field limiting local irradiation of bioon.


    com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.


    bioon.


    bioon.


    bioon.


    bioon.


    These researchers proposed, "In short, our research confirms the opposing regulatory effects between radiotherapy or immunotherapy and bioon.
    com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
    html">tumor- induced splenic Ter cells.
    "

    bioon.
    com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
    html">Tumor

    These researchers believe that these immunotherapies and combined treatments with radiotherapy are "worthy of further study to understand their interaction with bioon.
    com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
    html">tumor- promoting pathways.
    " (Bioon.
    com)

    bioon.
    com/course_video/chang-fei-bian-ma-RNA-yu-zhong-liu959063.
    html">Tumor

    References: 1.
    Yuzhu Hou et al.
    sciencemag.


    org/content/13/582/eabb0130" target="_blank">Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity .
    Science Translational Medicine, 2021, doi:10.


    References: 1.
    Yuzhu Hou et al.
    sciencemag.
    org/content/13/582/eabb0130" target="_blank">Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity .
    Science Translational Medicine, 2021, doi:10.
    1126/scitranslmed.
    abb0130.
    2.
    Study uncovers inhibitory role of'Ter cells' in cancer therapies
    https://medicalxpress.
    com/news/2021-02-uncovers-inhibitory-role-ter-cells.
    html sciencemag.
    org/content/13/582/eabb0130" target="_blank">Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.